FI70704C - Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet - Google Patents

Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet Download PDF

Info

Publication number
FI70704C
FI70704C FI791034A FI791034A FI70704C FI 70704 C FI70704 C FI 70704C FI 791034 A FI791034 A FI 791034A FI 791034 A FI791034 A FI 791034A FI 70704 C FI70704 C FI 70704C
Authority
FI
Finland
Prior art keywords
propoxy
dihydrocarbostyril
group
compound
crystals
Prior art date
Application number
FI791034A
Other languages
English (en)
Finnish (fi)
Other versions
FI791034A7 (fi
FI70704B (fi
Inventor
Kazuo Banno
Takafumi Fujioka
Yasuo Oshiro
Kazuyuki Nakagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of FI791034A7 publication Critical patent/FI791034A7/fi
Application granted granted Critical
Publication of FI70704B publication Critical patent/FI70704B/fi
Publication of FI70704C publication Critical patent/FI70704C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI791034A 1978-03-30 1979-03-28 Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet FI70704C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3778378 1978-03-30
JP3778378A JPS54130587A (en) 1978-03-30 1978-03-30 Carbostyryl derivative

Publications (3)

Publication Number Publication Date
FI791034A7 FI791034A7 (fi) 1979-10-01
FI70704B FI70704B (fi) 1986-06-26
FI70704C true FI70704C (fi) 1986-10-06

Family

ID=12507080

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791034A FI70704C (fi) 1978-03-30 1979-03-28 Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet

Country Status (21)

Country Link
US (2) US4734416A (enExample)
JP (1) JPS54130587A (enExample)
AT (1) AT376432B (enExample)
AU (1) AU515531B2 (enExample)
BE (1) BE875174A (enExample)
CA (1) CA1117110A (enExample)
CH (2) CH641455A5 (enExample)
DE (2) DE2953723C2 (enExample)
DK (1) DK158225C (enExample)
ES (4) ES479134A1 (enExample)
FI (1) FI70704C (enExample)
FR (1) FR2421174A1 (enExample)
GB (1) GB2017701B (enExample)
IT (1) IT1119284B (enExample)
MX (1) MX5862E (enExample)
NL (1) NL183189C (enExample)
NO (1) NO151321C (enExample)
PT (1) PT69422A (enExample)
SE (1) SE434945B (enExample)
SU (2) SU1140687A3 (enExample)
ZA (1) ZA791516B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS6129331A (ja) * 1985-03-13 1986-02-10 アラ−ガン・ハンフリ− 検眼装置
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
EP0255134B1 (en) * 1986-07-31 1993-03-03 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
EP0269383A3 (en) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2004043358A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
TWI258470B (en) * 2003-01-09 2006-07-21 Otsuka Pharma Co Ltd Process for preparing aripiprazole
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
MXPA05013365A (es) * 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
PT1613598E (pt) * 2003-12-16 2012-01-13 Teva Pharma Métodos para preparar formas cristalinas de aripiprazol
WO2005077904A1 (en) * 2004-02-05 2005-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing aripiprazole
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
CN101087760B (zh) * 2004-11-18 2011-09-28 斯索恩有限公司 结晶的阿立哌唑溶剂化物
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
EP1686126A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Salts of aripiprazole
CN101107242B (zh) * 2005-01-27 2011-08-10 桑多斯股份公司 阿立哌唑的盐
EP1858514B1 (en) * 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
WO2007035348A2 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007075871A2 (en) * 2005-12-22 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for reducing particle size of aripiprazole
WO2007092779A2 (en) * 2006-02-03 2007-08-16 Dr. Reddy's Laboratories Ltd. Aripiprazole co-crystals
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en) * 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US8039621B2 (en) * 2006-10-24 2011-10-18 Cambrex Charles City, Inc. Process for preparing anhydrous Aripirazole type I
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
RU2497819C2 (ru) * 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
PL2082735T3 (pl) 2008-01-23 2011-05-31 Helm Ag Amorficzny arypiprazol i sposób jego wytwarzania
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2009137843A2 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
KR20120065392A (ko) 2009-09-11 2012-06-20 오츠카 세이야쿠 가부시키가이샤 만성 동통 치료제
WO2011030213A1 (en) 2009-09-14 2011-03-17 Jubilant Organosys Limited Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2014031584A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
ES2963237A1 (es) * 2022-08-25 2024-03-25 Consejo Superior Investigacion Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA801037A (en) * 1968-12-10 Regnier Gilbert Procede de preparation de nouveaux derives du piperazino-phenylethanol
GB1021522A (en) * 1963-05-10 1966-03-02 Ici Ltd 2-quinolone derivatives
GB1075156A (en) * 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
NL131192C (enExample) * 1965-06-16
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3703522A (en) * 1967-03-30 1972-11-21 Mcneilab Inc Carbostyril derivatives
US3706749A (en) * 1967-03-30 1972-12-19 Mcneilab Inc N-acyl carbostyrils
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
CH523899A (de) * 1968-07-05 1972-06-15 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
BE884459Q (fr) * 1971-05-14 1981-01-26 Boehringer Mannheim Gmbh Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation
DE2335432A1 (de) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
JPS48103590A (enExample) * 1972-04-13 1973-12-25
US4256890A (en) * 1972-09-14 1981-03-17 Otsukapharmaceutical Co., Ltd. 3,4-Dihydrocarbostyril derivatives and process for producing the same
DE2354145A1 (de) * 1972-11-02 1974-05-16 Sandoz Ag Chinazolin-2(lh)-one und verfahren zu ihrer herstellung
DE2334009A1 (de) * 1973-07-04 1975-01-23 Boehringer Mannheim Gmbh Purin-derivate sowie verfahren zu ihrer herstellung
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4026895A (en) * 1973-09-08 1977-05-31 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4117228A (en) * 1973-09-08 1978-09-26 Eisai Co., Ltd. 1,3-benzodioxol derivatives
GB1451900A (en) * 1973-10-30 1976-10-06 Sandoz Ltd Quinolin-2-1h-ones
JPS5089376A (enExample) * 1973-12-19 1975-07-17
US4032528A (en) * 1974-03-25 1977-06-28 Sandoz, Inc. 1,4-substituted-quinolin-2(1h)-ones as cns agents
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2631317A1 (de) * 1975-07-23 1977-02-17 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
ES456325A1 (es) * 1976-02-27 1978-05-01 Sandoz Ag Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
CH619453A5 (enExample) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
US4210753A (en) * 1976-03-17 1980-07-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4110449A (en) * 1977-05-23 1978-08-29 E. R. Squibb & Sons, Inc. 2-substituted benzisothiazol-3-ones
US4166116A (en) * 1977-11-11 1979-08-28 Canadian Patents And Development Limited Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO151321B (no) 1984-12-10
IT1119284B (it) 1986-03-10
SE434945B (sv) 1984-08-27
ZA791516B (en) 1980-04-30
SU1140687A3 (ru) 1985-02-15
CA1117110A (en) 1982-01-26
NL183189C (nl) 1988-08-16
AU515531B2 (en) 1981-04-09
FI791034A7 (fi) 1979-10-01
ES479134A1 (es) 1980-06-16
FR2421174B1 (enExample) 1982-11-19
IT7967674A0 (it) 1979-03-30
ES486991A1 (es) 1980-10-01
ATA235179A (de) 1984-04-15
JPS54130587A (en) 1979-10-09
AT376432B (de) 1984-11-26
NL7902514A (nl) 1979-10-02
FR2421174A1 (fr) 1979-10-26
DK158225B (da) 1990-04-16
GB2017701A (en) 1979-10-10
JPS6223750B2 (enExample) 1987-05-25
BE875174A (fr) 1979-10-01
PT69422A (en) 1979-04-01
DK158225C (da) 1990-09-17
NO151321C (no) 1985-03-20
ES486992A1 (es) 1980-10-01
GB2017701B (en) 1983-03-16
US4824840A (en) 1989-04-25
MX5862E (es) 1984-08-13
CH641350A5 (de) 1984-02-29
US4734416A (en) 1988-03-29
SU1232144A3 (ru) 1986-05-15
SE7902794L (sv) 1979-10-01
DE2912105C2 (de) 1985-08-29
DK128679A (da) 1979-10-26
DE2912105A1 (de) 1979-10-11
CH641455A5 (de) 1984-02-29
NO791049L (no) 1979-10-02
DE2953723C2 (de) 1989-01-12
ES486990A1 (es) 1980-10-01
AU4548079A (en) 1979-10-04
FI70704B (fi) 1986-06-26

Similar Documents

Publication Publication Date Title
FI70704B (fi) Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet
DE69130412T2 (de) Pyrazolopyridinverbindung und Verfahren zu ihrer Herstellung
WO2000006550A1 (en) Phenylazole compounds, process for producing the same and drugs for hyperlipemia
KR970011298B1 (ko) 벤즈이미다졸류로부터 유도된 무진정성 항히스타민제
RO113242B1 (ro) Derivati de indol, procedee de preparare, compozitie farmaceutica si metoda de tratament
CA2400657A1 (en) Derivatives of quinoline as alpha-2 antagonists
JPH0587077B2 (enExample)
NZ514814A (en) Quinoline derivatives as inhibitors of MEK enzymes
FI76322C (fi) Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara karbostyrilderivat.
HU215125B (hu) Eljárás 3-[aril-(tio)karbonil]-1-amino-alkil-1H-indol-származékokat tartalmazó, glaukóma-elleni gyógyszerkészítmények előállítására
EP1037887B1 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
EP0577325A1 (en) Carbostyril derivatives and antiallergic agent
KR910009934B1 (ko) 카르바모일-2-피롤리디논 화합물
WO1989005803A1 (fr) Derives de 3,4-dihydro-2h-1,3-benzoxazine et leur utilisation en medecine
RU2138501C1 (ru) Имидазопиридиназолидиноны, их соли и лекарственное средство
KR930009355B1 (ko) 피리도[1, 2-a]피리미딘 유도체의 제조법
JPS6377856A (ja) 新規なフェニル、ピロリジン―２―イル置換５員複素環化合物およびその製造方法並びにこの化合物を有効成分とする抗精神病医薬組成物
WO2008135578A1 (en) Pyrazolo [3, 4-d] pyrimidine derivatives for the treatment of inflammation and/or allergic conditions
EP2970210B1 (en) Pyrazolylbenzo[d]imidazole derivatives
EP0204003A1 (en) 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same
US6593324B2 (en) Dervatives of quinoline as alpha-2 antagonists
JPS6331445B2 (enExample)
KR820002231B1 (ko) 신규 카르보스티릴 유도체의 제조방법
EP0686630B1 (en) Quinoline derivatives and pharmaceutical composition containing them
JPS63119467A (ja) カルボスチリル誘導体

Legal Events

Date Code Title Description
MA Patent expired
MA Patent expired

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.